Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report 2026

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Overview

• Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations market size has reached to $54.73 billion in 2025 • Expected to grow to $90.76 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: The Growing Drug Development And Manufacturing Activities Is Fueling The Growth Of The Market Due To Rising Demand For Novel Therapeutics And Accelerated Production Timelines • Market Trend: Advancement Of High-Concentration Biologic Formulation Platforms To Enhance Drug Stability And Delivery Efficiency • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

The key promising market opportunities in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market include: • Oral Solids (Segmentation By Dosage Form) → Expected gain of $13 Billion • Injectables (Segmentation By Dosage Form) → Expected gain of $13 Billion • Oral Liquids (Segmentation By Dosage Form) → Expected gain of $3 Billion

What Is Covered Under Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?

A pharmaceutical contract development and manufacturing organization (CDMO) for formulations refers to a company that provides outsourced services to develop and produce drug formulations for pharmaceutical firms. These services include activities such as formulation development, analytical testing, clinical trial material production, and large-scale commercial manufacturing. The main types of dosage forms for pharmaceutical contract development and manufacturing organizations (CDMO) for formulations are oral solids, oral liquids, injectables, topicals, inhalation products, transdermals and patches, and others. Oral solid dosage forms are medications taken by mouth, formulated to deliver the drug within the digestive system. It is used in various therapeutic areas such as oncology, cardiology, central nervous system, gastroenterology, infectious diseases, and endocrinology, and is used by several end-users, including pharmaceutical companies, biopharmaceutical companies, and others.

What Is The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Growth Forecast?

The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market size is expected to see rapid growth in the next few years. It will grow to $90.76 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to advancements in custom peptide synthesis technologies, expansion of commercial-scale gmp manufacturing, increasing outsourcing to cros and smes, development of lifecycle management and process optimization strategies, rising demand for clinical and preclinical peptide api manufacturing. Major trends in the forecast period include rising outsourcing of peptide api manufacturing to contract manufacturers, growth in gmp-grade production for clinical and commercial supply, increasing demand for custom peptide synthesis and purification services, expansion of peptide therapeutics pipelines across pharmaceutical companies, focus on process optimization and lifecycle management for peptide apis.

What Is The Driver Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?

The growing drug development and manufacturing activities are expected to propel the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market going forward. Drug development and manufacturing activities refer to the increasing efforts by pharmaceutical and biopharmaceutical companies to research, develop, and produce new drugs. Drug development and manufacturing activities are rising primarily due to the growing global demand for novel and effective therapeutics, which pushes companies to expand their development pipelines and speed up manufacturing timelines. A pharmaceutical CDMO aids drug development by formulating and optimizing dosage forms, performing stability testing, and ensuring regulatory compliance. It also manages scale-up and production, enabling faster, cost-efficient product launches. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association that represents the pharmaceutical industry in Europe, the total pharmaceutical production in Europe accounted for $422,803 million (€390,000 million) in 2023, up from $393,857 million (€363,300 million) in 2022. Therefore, growing drug development and manufacturing activities are driving the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations industry.

How Will The Drivers Impact Growth In The Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?

• Rising R&D Investments (High) – During the forecast period, the rising r&d investments is expected to become a key growth driver for the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market by 2030. Rising R&D investments in the pharmaceutical sector are significantly driving the CDMO formulations market by increasing the pipeline of new and complex drug candidates. As companies focus on innovation, they require specialized expertise in formulation development, analytical testing, and scale-up processes, which are often outsourced to CDMOs. This shift helps reduce internal costs and accelerates time-to-market for new therapies. Additionally, the growing emphasis on advanced drug delivery systems further boosts reliance on CDMO partners. • Increasing Medical Demands (Medium) – During the forecast period, the increasing medical demands is expected to emerge as a major factor driving the expansion of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market by 2030. The rising global burden of chronic diseases, aging populations, and improved access to healthcare is significantly increasing the demand for pharmaceutical products. This surge in medical needs compels pharmaceutical companies to accelerate drug development and expand production capacities. • Demand For Injectable Drugs (Low) – During the forecast period, the demand for injectable drugs is expected to act as a key growth catalyst for the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market by 2030. The rising demand for injectable drugs is significantly driving the pharmaceutical CDMO formulations market due to the increasing use of biologics, vaccines, and targeted therapies. Injectable formulations require sterile manufacturing environments, advanced technologies, and strict regulatory compliance, which encourages pharmaceutical companies to outsource these complex processes to specialized CDMOs. This outsourcing helps reduce infrastructure costs and accelerates time-to-market. As the pipeline of injectable therapies continues to expand, CDMOs play a crucial role in supporting scalable and high-quality production. Consequently, this trend strengthens market growth by increasing reliance on external development and manufacturing partners.

How Will The Restraints Impact Growth In The Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?

• Regulatory Complexities And Compliance Challenges (High) – During the forecast period, the regulatory complexities and compliance challenges act as a major restraint in the pharmaceutical CDMO formulations market due to the stringent standards imposed by global health authorities. CDMOs must adhere to diverse and frequently evolving regulations related to safety, quality, and manufacturing practices, which increases operational burden and costs. The need for extensive documentation, audits, and approvals can delay product development and commercialization timelines. Additionally, non-compliance risks penalties, product recalls, and reputational damage, making companies more cautious in outsourcing. As a result, these regulatory pressures can slow market growth and limit the entry of smaller players. • High Capital And Infrastructure Requirements (Medium) – During the forecast period, the high capital and infrastructure requirements act as a significant restraint in the pharmaceutical CDMO formulations market by increasing the cost of entry and expansion. Establishing compliant manufacturing facilities demands substantial investment in specialized equipment, cleanrooms, and advanced technologies. Ongoing expenses for maintenance, upgrades, and regulatory compliance further add to the financial burden. Smaller or emerging CDMOs may find it difficult to compete or scale operations under such conditions. As a result, these high costs can limit market participation and slow overall industry growth. • Intellectual Property And Quality Control Concerns (Low) – During the forecast period, the intellectual property and quality control concerns act as a restraint in the pharmaceutical CDMO formulations market by creating hesitation among companies to outsource critical processes. Firms are often cautious about sharing proprietary formulations and sensitive data with external partners due to the risk of IP leakage or misuse. Additionally, variations in manufacturing standards across CDMOs can raise concerns about product consistency, safety, and regulatory compliance. These risks may lead companies to retain in-house production for high-value or complex drugs. As a result, such concerns can limit outsourcing adoption and slow overall market growth.

Key Players In The Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.

Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Trends and Insights

Major companies operating in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are focusing on developing advanced solutions, such as biologic formulation platforms, to enhance drug stability and accelerate time-to-market for complex biologic therapies. Biologic formulation platforms are specialized systems designed to create stable and efficient formulations of biologic drugs. They fine-tune elements such as pH, excipients, and delivery methods to enhance stability, bioavailability, and safety across the product lifecycle. For instance, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing organization, launched WuXiHigh 2.0, a next-generation high-concentration formulation platform. This advanced platform enables biologic formulations with protein concentrations up to 230 mg/mL, surpassing the current Food and Drug Administration-approved maximum of 200 mg/mL, while reducing viscosity by up to 90% through proprietary excipient blends and high-throughput instrumentation. It addresses key challenges in developing high-concentration biologics, such as viscosity and aggregation, and is designed to improve injection efficiency, patient compliance, and manufacturing outcomes across clinical and commercial stages.

What Are Latest Mergers And Acquisitions In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?

In February 2025, Jabil Inc., a US-based provider of engineering, manufacturing, and supply chain solutions, acquired Pharmaceutics International Inc. (Pii) for an undisclosed amount. The acquisition aims to enhance Jabil’s pharmaceutical manufacturing and development capabilities by leveraging Pii’s expertise in aseptic filling, lyophilization, and oral solid dose production. This strengthens Jabil’s position in parenteral drug delivery and expands its end-to-end support across clinical and commercial manufacturing. Pharmaceutics International Inc. (Pii) is a US-based pharmaceutical contract development and manufacturing organization that provides formulation development services for injectable to oral drug forms.

What Defines the Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market consists of revenues earned by entities by providing services such as analytical and stability testing, formulation development, process development and scale-up, regulatory support and documentation, and commercial-scale manufacturing and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market also includes sales of suppositories, ophthalmic preparations, buccal and sublingual tablets, liposomal formulations, and microneedle patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report 2026?

The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.